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Abstract
Purpose To evaluate the impact of dosimetry based on
MAA SPECT/CT for the prediction of response, toxicity
and survival, and for treatment planning in patients with
hepatocellular carcinoma (HCC) treated with 90Y-loaded
glass microspheres (TheraSphere®).
Methods TheraSphere® was administered to 71 patients
with inoperable HCC. MAA SPECT/CT quantitative anal-
ysis was used for the calculation of the tumour dose (TD),
healthy injected liver dose (HILD), and total injected liver
dose. Response was evaluated at 3 months using EASL
criteria. Time to progression (TTP) and overall survival
(OS) were evaluated using the Kaplan-Meier method. Fac-
tors potentially associated with liver toxicity were combined
to construct a liver toxicity score (LTS).
Results The response rate was 78.8 %. Median TD were
342 Gy for responding lesions and 191 Gy for
nonresponding lesions (p<0.001). With a threshold TD of
205 Gy, MAA SPECT/CT predicted response with a sensitiv-
ity of 100 % and overall accuracy of 90 %. Based on TD and
HILD, 17 patients underwent treatment intensification
resulting in a good response rate (76.4 %), without increased
grade III liver toxicity. The median TTP and OS were
5.5 months (2–9.5 months) and 11.5 months (2–31 months),
respectively, in patients with TD <205 Gy and 13 months (10–
16 months) and 23.2 months (17.5–28.5 months), respectively,
in those with TD >205 Gy (p=0.0015 and not significant).
Among patients with portal vein thrombosis (PVT) (n=33), the
median TTP and OS were 4.5 months (2–7 months) and
5 months (2–8 months), respectively, in patients with TD
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<205 Gy and 10 months (6–15.2 months) and 21.5 months
(12–28.5months), respectively, in those with TD >205 Gy (p=
0.039 and 0.005). The median OS was 24.5 months (18–
28.5 months) in PVT patients with TD >205 Gy and good
PVT targeting on MAA SPECT/CT. The LTS was able to
detect severe liver toxicity (n=6) with a sensitivity of 83 %
and overall accuracy of 97 %.
Conclusion Dosimetry based on MAA SPECT/CT was able
to accurately predict response and survival in patients treat-
ed with glass microspheres. This method can be used to
adapt the injected activity without increasing liver toxicity,
thus defining a new concept of boosted selective internal
radiation therapy (B-SIRT). This new concept and LTS
enable fully personalized treatment planning with glass mi-
crospheres to be achieved.
Keywords Radioembolization .Microspheres . Dosimetry .
Liver . Radionuclide therapy
Introduction
Hepatocellular carcinoma (HCC), a highly prevalent tu-
mour, is the third most common cause of cancer-induced
death worldwide with more than 500,000 deaths per year
[1]. The clinical effectiveness of selective internal radiation
therapy (SIRT) using 131I-radiolabelled lipiodol was first
demonstrated in 1994 based on a randomized study in
patients with portal vein thrombosis (PVT) [2]. Despite its
proven efficacy, 131I-radiolabelled lipiodol has not been
widely used due to major radioprotection constraints. The
development of 90Y-loaded microspheres is a great advance,
and 90Y-loaded microspheres are currently increasingly used
in patients with Barcelona Clinic Liver Cancer stage B
(intermediate stage) liver cancer and in patients with PVT,
with promising clinical outcomes [3–6]. In particular, one
retrospective study has shown that glass microspheres are
able to achieve a significantly improved rate of down-
staging compared to chemoembolization, with significantly
fewer side effects [7], while another study has shown that
progression-free survival (PFS) is significantly improved
[8]. Regarding safety considerations, to identify lung and
digestive shunts, SIRT with 90Y-loaded microspheres is
preceded by diagnostic angiography and hepatic perfusion
scintigraphy with 99mTc macroaggregated albumin (MAA).
SIRT is currently recognized as a potential approach to local
and regional HCC therapy by various scientific societies and
expert groups, including the European Society of Medical
Oncology [9].
The concept of SIRT is to deliver a tumoricidal dose to
the tumour while sparing healthy liver tissue [10, 11]. To
achieve the best efficacy and lowest toxicity, the tumour
absorbed dose (TD) and the dose absorbed by healthy liver
tissue are two key parameters that need to be known and
controlled when using SIRT. From a radiobiological point of
view, optimal perfusion and blood flow are prerequisites for
SIRT, in contrast to chemoembolization, as oxygen in-
creases radiotoxicity [11]. However, limited data are avail-
able concerning tumour dosimetry, and recommendations
are still based on liver dosimetry. The goal of therapy with
glass microspheres is to deliver a radiation dose of 120±
20 Gy to the injected liver volume (ILD), with the dose
calculation based on the accepted simplified formula [12]:
ILD = IA × (1 − S) × 50/W, where IA is the activity in
gigabecquerels to be injected, S is the percentage pulmonary
shunt as measured by a MAA liver perfusion scan, and W is
the mass in kilograms of the liver volume to be treated.
When using resin microspheres, guidelines relying on
expert opinion recommend using the partition model [11].
For delineable tumours, an ILD of 120 Gy to the tumour
compartment is recommended and 50–70 Gy to the healthy
liver, depending on the clinical scenario. For nondelineable
tumours the body surface area method is used.
Preliminary results have shown that there is a close
correlation between TD and response with the use of glass
microspheres [5, 13, 14]. In light of this, our team has put
forward the possibility of using predictive dosimetry based
on MAA SPECT/CT in treatment intensification, as we have
previously identified a mean tumour threshold dose
(TTD) of 205 Gy to achieve a response [14]. The aim
of this retrospective study was to determine the impact
of MAA SPECT/CT dosimetry on treatment planning and
survival when using glass microsphere therapy in a large




Data from all 86 HCC patients referred to our institution for
SIRT with 90Y-loaded glass microsphere (TheraSphere®;
Nordion, Ottawa, Canada) in a palliative setting were
analysed. After exclusion of 15 patients, 11 following diag-
nostic angiography (high hepatopulmonary shunting, 4;
poor tumour targeting, 6; noncorrectable digestive shunt,
1) and 4 due to lack of SPECT/CT acquisitions, 71 treated
patients were included in this retrospective study. Written
informed consent was obtained from each patient, and the
use of SIRT was approved by the ethics committee of our
university hospital. The indication for SIRT was clarified
during a HCC multidisciplinary staff meeting. SIRT was
used as first-line treatment in 35 patients, and for recur-
rences in the remaining 36 patients (15 after surgery, 14
after chemoembolization, 5 after treatment with sorafenib,
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and the remaining 2 after 131I-lipiodol therapy). Patients
were considered unsuitable for chemoembolization because
of the presence of different conditions (PVT, multifocal or
voluminous lesions, incomplete response, or progression
after several cycles of chemoembolization). Most patients
(33) had intermediate or advanced stage disease with PVT
(12 main, lobar, and 21 segmental), but without extrahepatic
spread. Patient and tumour characteristics are detailed in
Table 1.
Planning and administration of 90Y-loaded glass
microspheres
Microspheres were administered as described by Salem et
al. [12]. After diagnostic angiography, a liver perfusion scan
was performed, following injection of 185 MBq of MAA
into the hepatic artery. Planar scans were acquired for lung
shunt evaluation. In addition, SPECT/CT scans acquired
(window 140±7.5 KeV, 32 projections, 180°, 128 × 128,
30 s per projection; Symbia T2 gantry; Siemens, Germany),
and data was reconstructed using an iterative method
(OSEM, five iterations, eight subsets) with attenuation
(low-dose CT attenuation map) and scatter corrections
(Jaszczak method, diffusion window 120±7.5 KeV), and
then visualized with and without CT scan data fusion.
As previously described, the “volumetric analysis” soft-
ware (Syngo workstation; Siemens) was used to quantita-
tively analyse tumour and nontumour liver tissue uptake
[15]. This software enables semiautomatic generation of
the volume of interest (VOI) in the injected liver and tumour
using an isocontour method. For each VOI, the threshold
value was adjusted so that the isocontours of the MAA
distribution volume on the fusion images matched the liver
and tumour boundaries. Regarding tumour delineation, the
model was applied to all tumours visualized by SPECT/CT,
including small and infiltrative tumours. These VOIs
were then used to measure the MAA volume of distri-
bution in the injected liver and tumour, as well as the
total activity contained in the injected liver and tumour.
In necrotic tumours, the volume of the hypofixing area was
not taken into account by the software (Fig. 1). Volume and
activity in the injected healthy liver were calculated by
subtraction.
The activity to be injected was calculated conventionally
for the schedule in order to achieve an ILD of 120±20 Gy
(without exceeding 30 Gy for the lungs) in the first 20
patients. After the 20th patient, the standard approach was
used to verify that the tumour dose was effectively higher
than the TTD of 205 Gy. If this threshold was not reached,
patients underwent treatment intensification (increasing the
activity to be injected, i.e. boosted patients) with the goal of
achieving a tumour dose exceeding 205 Gy while
maintaining the healthy injected liver dose (HILD) below
Table 1 Demographic and baseline characteristics of the patients (n=71)
Clinical variable Value



















Tumour size, mean ± SD (cm) 7.1±3.3
Tumour involvement, mean ± SD (%) 25±21
Tumour involvement, % (n)
≥70 3
≥50 to <70 10







Mean ± SD 4 528±63 173
Median 42
Bilirubin level, mean ± SD (μmol/ml) 17±8.9
Bilirubin >34 μmol/ml (n) 2
Alanine aminotransferase level, mean ± SD (U/l) 52.4±34.6
Alanine aminotransferase >5 times normal (n) 2
Albumin level, mean ± SD (U/l) 40±4.8
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120 Gy, as previously described [14]. The glass micro-
spheres were injected using a lobar approach 8 to 15 days
later. In patients with bilateral disease, two lobar treatments
were administered separately at an interval of 6 to 8 weeks.
No specific activity adaptation was made with respect to the
bilateral nature of the lesions, nor was any specific activity
adaptation made in patients regarding the HILD who were
potentially at risk of hepatic toxicity (bilateral disease,
Child-Pugh class B).
Response evaluation
Tumour response was assessed using the European Associa-
tion for the Study of the Liver (EASL) criteria [16]. Triphasic
CT scans were performed 3 months after treatment, and then
every 3 months until progression or death. For EASL response
evaluation, complete response (CR) was defined as absence of
any enhancing tissue, partial response (PR) as a decrease
of >50 % in enhancing tissue, progressive disease (PD) as
an increase of >25 % in the size of one or more measurable
lesion(s) or the appearance of new lesions, and stable disease
(SD) as a tumour response between PR and PD.
Liver toxicity factors
Only definitive grade III or higher liver toxicity was con-
sidered by means of the Common Terminology Criteria for
Adverse Events (v4). Imputability of the suspected toxicity
was defined according to ICH E2B (R3) guidelines, mean-
ing that toxicity was attributed to disease progression in
patients with both liver toxicity and evidence of largely
PD. Different parameters were evaluated: presence of PVT,
alpha-fetoprotein level, treatment line (first line versus sec-
ond or further lines), bilirubin level (≤ or >34 μmol/ml),
alanine aminotransferase (ALT) level (less than or more than
Fig. 1 VOI delineation in a 77-year-old patient with a large HCC of
the right lobe associated with two small lesions of the left lobe who
underwent treatment intensification (boosted). a Initial CT slice shows
heterogeneous HCC of 12.3 cm with a central area of necrosis. b, d
MAA SPECT/CT with high uptake and a hypofixing area: b VOI
delineation for the tumour; d VOI delineation for the injected liver.
The patient underwent treatment intensification with 3.5 GBq of 90Y-
loaded glass microspheres (ILD 162 Gy, TD 280 Gy, HILD 54 Gy).
Using the standard approach, only 2.6 GBq of 90Y-loaded glass micro-
spheres would have been used to achieve an ILD of 120 Gy, then the
TD would have been only 207 Gy, and the HILD 38 Gy. c CT slice
3 months after injection shows EASL partial response of the treated
tumour of the right lobe. The left lesions were treated by hyperselective
chemoembolization due to their small size. The patient was still alive,
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five times normal), HILD (>40, 6, 80, 100 and 120 Gy),
Child-Pugh class and score (A or B7), tumour involvement
(< or >70 %), hepatic reserve (percentage of nonirradiated
liver, < or >30 %), severe underlying biliary disease (biliary
cirrhosis or intrahepatic biliary dilatation), presence of com-
plete PVT of the trunk without MAA targeting on
SPECT/CT, as well as the combination of HILD (>40, 60,
80, 100, and 120 Gy) and hepatic reserve <30 %.
Liver toxicity scores (LTS) were based on recognized
pretreatment factors previously identified as being linked with
toxicity as well as factors identified in this study, including
ALT level more than five times normal, bilirubin level
>35 μmol/ml, tumour involvement >70 %, Child-Pugh class
B, previous treatment, severe underlying biliary disease, pres-
ence of large PVT of the trunk without MAA targeting on
SPECT/CT, and a combined profile of HILD >120 Gy with a
hepatic reserve <30 %. Different weightings for each param-
eter were used to create different LTS (Table 2):
– LTS 1: one point for each parameter present
– LTS 2: one point for the first five parameters and two
points for the last three
– LTS 3: one point for the first five parameters and three
points for the last three
For each LTS, different cut-off values were evaluated in
order to obtain the best score for liver toxicity detection. A
patient’s score was considered positive (predictive of liver
toxicity) if its value was higher than or equal to a predefined
cut-off value.
Statistics
Quantitative values are expressed as means ± standard de-
viation. The TD in responding and nonresponding patients
were compared using Wilcoxon’s distribution-free compar-
ison test. Regarding the responses, a true-positive (TP)
response was defined as an objective response (CR + PR)
obtained when the TD was higher or equal to the TTD. A
true-negative (TN) response was defined as TD < TTD,
without an objective response at 3 months. A false-
negative (FN) response was defined as TD < TTD, with an
objective response at 3 months. A false-positive (FP) re-
sponse was defined as TD ≥ TTD, without an objective
response at 3 months.
Univariate analysis and Wilcoxon’s distribution-free
comparison test were used to identify parameters associated
with tumour response, PFS, and overall survival (OS). Test-
ed parameters for response were: injected activity, ILD
(gray), HILD (gray), TD (gray), tumour to nontumour ratio,
tumour activity (percent injected activity), alpha-fetoprotein
level (kIU/l), and tumour size (cm). The tested parameters
for survival were: tumour type (unifocal versus multifocal
and infiltrative), size (≤5 versus >5 cm), PVT (present),
alpha-fetoprotein level (≤400 versus >400 kIU/l), Child-
Pugh class (A versus B7), CLIP (stage 0, 1 or 2 versus 3
or 4) and TD (< versus ≥205 Gy). Data selected after
univariate analysis was then subjected to multivariate anal-
ysis using logistic regression testing. Time to progression
(TTP) was defined as the time between treatment and
disease progression confirmed on CT scan. OS was
defined as the time between treatment and the most recent
follow-up or death. Survival rates were estimated using the
Kaplan-Meier method, and they were compared using the
log-rank test.
For liver toxicity, univariate analysis was carried out
using Fisher’s exact test, and multivariate analysis using
a logistic regression. Liver toxicity scoring systems
were compared using ROC analysis. Response rates
and toxicity were compared using the chi-squared test.
Finally the LTS were compared with ROC curves. SAS
software was employed for the statistical analyses, with
a significance threshold set at p≤0.05.
Results
In total, 93 injections were administered to 71 patients, of
whom 22 received two treatments (8 for bilateral lesions, 2
Table 2 Liver toxicity score
(LTS)
For each variable, zero points are
attributed if it is absent, and 1 to
3 points are attributed depending
on the scoring system used.
The patient score is obtained by
adding the number of points at-
tributed to each variable.
A patient’s score is considered pos-
itive (predictive of liver toxicity) if
its value is higher than or equal to a
predefined cut-off value.
Variable LTS 1 LTS 2 LTS 3
ALT level more than five times normal 0 or 1 0 or 1 0 or 1
Bilirubin level >35 μmol/ml 0 or 1 0 or 1 0 or 1
Tumour involvement >70 % 0 or 1 0 or 1 0 or 1
Child-Pugh class B 0 or 1 0 or 1 0 or 1
Previous treatment 0 or 1 0 or 1 0 or 1
Severe underlying biliary disease 0 or 1 0 or 2 0 or 3
Main PVT without MAA targeting 0 or 1 0 or 2 0 or 3
HILD >120 Gy and hepatic reserve <30 % 0 or 1 0 or 2 0 or 3
Patient score 0 to 8 0 to 11 0 to 14
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for incomplete injection of the initial, 12 for incomplete
response or recurrence after the first injection). For the
overall population, the mean 90Y-loaded glass microsphere
injected activity was 2.9±1.5 GBq, the mean ILD was 124±
35 Gy, and the mean HILD was 76±35 Gy.
Response evaluation
The 3-month response rate was 78.8 %, comprising 7 patients
with CR, 49 with PR, 11 with SD and 4 with PD. The response
rate was 55 % in the first 20 patients treated without intensifi-
cation intent and 86 % in the following 51 patients treated with
intensification intent (p=0.001). Based on 99mTc-MAA
SPECT/CT, TD was 342±116 Gy for responding lesions,
and 191±89 Gy for nonresponding lesions (p<0.001). Con-
sidering a TTD of 205 Gy, MAA SPECT/CT predicted re-
sponse with a sensitivity of 100 % and overall accuracy of
90% (no FN, seven FP). Eight patients with a TD <205 Gy did
not respond to treatment, while 56 out of 63 patients with a TD
>205 Gy did respond. Of the seven patients with a FP re-
sponse, four had a TD <275 Gy (between 205 and 275 Gy),
which corresponds to a FP rate of 15.4 %. The three remaining
patients with a FP response had a TD >275 Gy corresponding
to a FP rate of 8.1 % when taking into account only patients
receiving a TD >275 Gy. Finally, the FP rate was 0 % in
patients with TD >350 Gy.
The response rate was 81 % in the 33 patients with PVT
(3 with CR, 24 with PR, 4 with SD and 2 with PD), of
whom nine had partial or total portal vein recanalization
(Fig. 2). Five patients with PVT (i.e. 15.6 %) were accu-
rately downstaged, and two of these underwent treatment
intensification. One of these five patients refused transplan-
tation, and four underwent lobar hepatectomy.
MAA uptake in PVT on SPECT/CTwas observed in 25 of
the 26 responding patients (Fig. 2), but only in one of the six
nonresponding patients who had a very large tumour resulting
in a low tumour dose. In total, 12 patients hadmain PVT. Eight
of these showed good MAA targeting, of whom seven were
responders, and tolerated the treatment well, and one did not
responding but had a low TD. The remaining four showed no
MAA uptake, and all four had severe liver toxicity, which was
transient in one, and definitive in the other three.
In the 21 patients with segmental or lobar PVT, the
response rate was 90.5 %. In the univariate analysis, only
the tumour to nontumour ratio and the TD proved to be
significantly correlated with response (p=0.01 and 0.001,
respectively). In the multivariate analysis, TD was still
correlated with response (p=0.019).
Treatment intensification
Overall, 17 patients received a boost, i.e. 24 % of the whole
population (n=71), but after identification of the concept
and the TTD (after the 20th patient) the intensification rate
was 33 % (17/51 patients). The intensification rate was only
5 % in patients with lesions <5 cm versus 50 % in those with
lesions ≥5 cm. In patients with PVT, the intensification rate
was 38 %. Only two patients with bilateral lesions
underwent intensification, which was performed only for
the first treatment. The second lobe was treated 6 to 8 weeks
later using the standard dosimetric approach, without com-
plications. Intensification parameters are presented in
Table 3.
Survival analysis
The median TTP was 11 months (95 % CI 8–15 months)
and the median OS was 23 months (95 % CI 15.3–
28 months). In patients with TD <205 Gy, the median TTP
was 5.5 months (95 % CI 2–9.5 months) versus 13 months
(95 % CI 10–16 months) in those with TD >205 Gy (p=
0.0038). In patients with TD <205 Gy, the median OS was
11.5 months (95 % CI 2–30.7 months) versus 23.2 months
(95 % CI 17.5–28.5 months) in those with TD >205 Gy (not
significant; Fig. 3).
In patients with PVT, the median TTP was 10 months
(95 % CI 6–15 months) and the median OS was 18.2 months
(95 % CI 11–27 months). In patients with PVT and TD
<205 Gy, the median TTP was 4.5 months (95 % CI 2–
7 months) versus 10 months (95 % CI 6–15.2 months) in
those with TD >205 Gy (p=0.048), while in patients with
PVT and TD <205 Gy, the median OS was 5 months (95 %
CI 2–8 months) versus 21.5 months (95 % CI 18–
28.5 months) in those with TD >205 Gy (p=0.005; Fig. 4).
In patients with PVT, TD <205 Gy and/or no MAA
targeting of the PVT (n=5), the median TTP and OS were
2 months (95 % CI 2–7 months) and 3 months (95 % CI 2–
8 months), respectively, versus 13 months (95 % CI 6–
15 months; p=0.0009) and 24.5 months (95 % CI 18–
28.5 months; p<0.0001), respectively, in patients with
PVT, TD >205 Gy and good PVT targeting (n=28, i.e.
85 % of patients with PVT; Fig. 5).
Lastly, in patients with segmental or lobar PVT, all of whom
exhibited a TD higher than 205 Gy, the median TTP and OS
were 10 months (95 % CI 6–18 months) and 24.50 months
(95 % CI 12–28.7 months), respectively. In Child-Pugh class A
patients (n=18), the median TTP and OS were 13 months
(95 % CI 7–18 months) and 24.5 months (95 % CI 11 months
to infinity), respectively (Fig. 6), versus 6 months (95 % CI 6–
10months) and 18months (95%CI 17.5–27months) in Child-
Pugh class B patients (n=3; not significant).
The only parameters that were correlated with PFS in the
univariate analysis were alpha-fetoprotein level and TD (p=
0.009 and 0.0002, respectively). Notably, PVT was shown
not to be significantly correlated with PFS. In the multivar-
iate analysis, only TD was still significantly associated with
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PFS (p<0.0001). The univariate analysis revealed that TD
was the only parameter that was correlated with OS (p=
0.04), whereas no parameter was significantly correlated
with OS in the multivariate analysis.
Hepatic toxicity and global tolerance
No deaths during the first month of treatment were
reported. Six patients developed permanent grade 3 or
higher hepatic toxicity beginning during the month fol-
lowing treatment without evidence of progression. The
toxicity rate was not significantly different between the pa-
tients without treatment intensification (9.2%, 5/54) and those
who underwent treatment intensification (5.8 %, 1/17; not
significant). One patient with biliary cirrhosis, who had a
combination of HILD >120 Gy and hepatic reserve <30 %,
died of liver failure at 2 months. Three patients with deepmain
PVT without MAA uptake died of liver failure at 3, 3 and
3.5 months, respectively. One patient with well-compensated
cirrhosis (Child-Pugh class A5) and a relatively small tumour
had unexplained refractory ascites and died at 7 months of
ascites infection. The remaining patient developed grade 3
ascites following treatment and died at 14 months of hepatic
Table 3 Boosted patients (n=17), baseline characteristics, percentage
of intensification, dosimetry and response
Parameter Value
Tumour involvement, mean ± SD (%) 42.1±17
Tumour size, mean ± SD (cm) 9.1±3.2
PVT, yes/no (n) 12/5
Child-Pugh class A/B (n) 16/1
Injected activity, mean ± SD (GBq) 3.4±1.6
Boost, mean ± SD (%)a 40±9.8
ILD, mean ± SD (Gy) 192±49
TD, mean ± SD (Gy) 338±108
HILD, mean ± SD (Gy) 84±37
Response rate (%) 76.4
a Percent increase in the injected activity with reference to the standard
activity that would have been injected to achieve a ILD of 120 Gy.
Fig. 2 A 62-year-old patient
with a large HCC and main
PVT who underwent treatment
intensification (boosted). The
patient showed a major
response with revascularization
of the portal vein. a–c Initial
imaging: CT slices show a
heterogeneous HCC of 9.6 cm
(a) with main PVT (b); MAA
SPECT/CT image shows high
uptake in the main PVT (c) The
patient underwent treatment
intensification with 1.16 GBq
of 90Y-loaded glass
microspheres (ILD 211 Gy, TD
285 Gy, HILD 65 Gy). Using
the standard approach only
0.56 GBq of 90Y-loaded glass
microspheres would have been
used to achieve an ILD of
120 Gy, then the TD would
have been only 162 Gy and the
HILD 37 Gy. d, e CT slices
3 months after injection show
EASL partial response of the
tumour (d) and main portal vein
revascularization (e). The
patient subsequently received a
left hepatectomy
(with complete tumour
resection). PFS was 15 months
with lung recurrence only. The
patient was still alive at the
most recent follow-up visit
(18 months)
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failure without evidence of disease progression. He had a
combination of HILD >120 Gy and hepatic reserve <30 %.
Only one of these patients exhibiting complete main PVT
withoutMAA uptake had undergone treatment intensification,
while the five others received standard doses (120±Gy to the
injected liver).
In the univariate analysis, only severe biliary disease
(p=0.006), large main PVT without MAA uptake
(p=0.0014), a combination of HILD >100 Gy and he-
patic reserve <30 % (p=0.032), and combination of
HILD >120 Gy and hepatic reserve <30 % (p=0.017)
were significantly associated with a risk of liver toxic-
ity, as shown in Table 4. In the multivariate analysis,
severe biliary disease, main PVT without MAA uptake
and combination of HILD >120 Gy and hepatic reserve
<30 % were still significantly associated with liver
toxicity (Table 4).
LTS 3 with a cut-off value of 3 points showed the
best diagnostic performance (Fig. 7). It was able to
predict severe permanent liver toxicity with a sensitivity
of 83 %, a negative predictive value of 98 %, a positive
predictive value of 71 %, and an overall accuracy of
97 %.
Furthermore, discrete to moderate asthenia was frequent-
ly reported, whereas episodes of pain were less commonly
noted. One patient presented with septicaemia, probably
caused by diagnostic angiography. No other severe extrahe-
patic complications were observed.
Discussion
There are five important results of this study: confirmation
of the accuracy of MAA SPECT/CT dosimetry in predicting
response, development of the intensification concept, good
results in patients with PVT, identification of an accurate
toxicity scoring system, and finally availability of a fully
personalized approach. Indeed, our study confirmed pre-
vious preliminary results reported by Mazzaferro et al.
[5], Chiesa et al. [13] and our team [14], notably the
high correlation between TD and response using glass
microspheres, along with a TTD necessary to achieve a
response. This point is evident from a radiobiological point of
view, as radioinduced damage responds to an “all or nothing”
concept, with no damage occurring below the TTD and lethal
damage occurring above the TTD (the higher the TD above
the TTD, the greater the damage). In the current study, the
TTD of 205 Gy showed good diagnostic performance in
selecting responders prior to treatment initiation, with a sen-
sitivity of 100 % and an accuracy of 90 %. We observed a FP
Fig. 3 Kaplan-Meier estimates of TTP (a) and OS (b) for the whole
population (n=71) stratified by TD
Fig. 4 Kaplan-Meier estimates of TTP (a) and OS (b) in patients with
PVT (n=33) stratified by TD
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response prediction in seven patients (i.e. patients with TD
>205 Gy and no response). These were patients with large
lesions (mean size 9.2±3.4 cm), with a large area of tumour
necrosis seen in three of them prior to treatment, and thus
presenting a higher risk of hypoxia-induced radioresistance.
Even if the TTD identified in the three studies (5, 13, 14)
were different, probably due to different dosimetric approaches
(MIRD approach and mean TD in one study, BED approach
and voxel TD in the other), its identification has a major
impact. To date, no factors predicting response or survival
other than TD have been identified, and even the recent study
conducted by Sato et al. failed to establish a correlation be-
tween lesion vascularization and survival [17]. The fact that a
TTD has been identified by two independent teams using
different dosimetric approaches underlines the robustness of
dosimetry based onMAASPECT/CTwith glass microspheres.
Given thatMAA SPECT/CT dosimetry is available prior to
the injection of microspheres, treatment intensification can be
proposed for patients with a TD just below or close to the
TTD, which is in accordance with the new concept of boosted
SIRT (B-SIRT). In our study, we applied this new concept to
17 patients, with a satisfactory clinical outcome: the response
rate in these difficult patients with large lesions was 76%, and
the severe liver toxicity rate was only 5.8 %, versus 9.2 % in
nonboosted patients. As the FP rate for response detection was
lower in patients receiving a TD >275 Gy compared to those
receiving a lower TD (i.e. 8.1 % versus 15.4 %) and as there
were no patients with a FP response among those who re-
ceived a TD ≥350 Gy, treatment intensification to obtain a TD
above the TTD of 205 Gy and could even exceed 275 Gy or
eventually 350 Gy may be possible.
It is probably preferable to optimize the activity rather
than perform several treatments in succession such as in
fractionated external beam radiotherapy as proposed by
several other teams [18]. Previously, we have demonstrated
using 131I-lipiodol that the TD is more effective following
initial treatment (248±176 Gy) rather than after the second
treatment (152 ± 122 Gy), which suggests that the
intratumour accumulation of the therapeutic agent decreases
under the effect of previous treatments due to redistribution
from tumour tissue into nontumour liver tissue [19].
It should be noted that the concept of intensification
appears to be of major interest in patients with PVT (38 %
of patients) and for those with lesions ≥5 cm (50 % of
patients). This point is of particular interest, as a complete
histological response has been reported following glass mi-
crosphere administration in only 33 % of tumours exceeding
5 cm [20]. Therefore, the concept of treatment
Fig. 6 Kaplan-Meier estimates of TTP (a) and OS (b) in Child-Pugh







Poor candidates, p<0.0001 
Fig. 5 Kaplan-Meyer estimates of TTP (a) and OS (b) for poor (n=5)
or good PVT (n=28) candidates
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intensification could be associated with a significantly in-
creased efficacy of glass microspheres for lesions larger than
5 cm. Our clinical results were particularly interesting in
patients PVT. The OS achieved, 18.2 months and
24.5 months for Child-Pugh class A patients with segmental
or lobar PVT, compared favourably with that reported by
other teams using glass microspheres (between 10 and
13 months [3–5]) or resin microspheres (10.0 months [6]),
and even sorafenib (8.1 months [21]). These good results
may be accounted for by this new concept of treatment
intensification. Nonetheless, our positive results must be
confirmed in a randomized study.
Another major finding of our study was the identifi-
cation of a relationship between TD and survival. Sur-
vival can be predicted using a TTD of 205 Gy. When
the dose delivered to the tumour was equal to or higher
than this threshold value, median TTP increased from
5.5 to 13 months (p=0.0038), and OS from 11.5 to
23.2 months. The results were even more convincing
in patients with PVT with an OS of only 5 months for a
TD <205 Gy and 21.5 months for a TD >205 Gy (p=
0.005). These results (good predictive value for re-
sponse and survival of MAA dosimetry) seem less re-
producible when using resin microspheres. The two
products differ, as resin microspheres have a more em-
bolic effect, and their radiobiological effects are proba-
bly slightly different [22]. Published results regarding
MAA scintigraphy and dosimetry are discordant. Using
planar scintigraphy and the partition model, Ho et al.
[23] reported a response rate in HCC of 37.5 % for a
TD >225 Gy versus only 10.3 % for a TD ≤225 Gy (p
<0.006). However, two recent studies have shown an
overall poor correlation between the uptakes of MAA
and 90Y-resin microspheres [24, 25], with a good corre-
lation found in some patients and a very poor correla-
tion in others [24]. Further work on resin microspheres
dosimetry is still required, and the concept of treatment
intensification based on MAA SPECT/CT dosimetry
Table 4 Factors associated with permanent grade 3 or higher liver toxicity
Variable Univariate analysis Multivariate analysis
Child-Pugh class (A or B) ns –
ALT (≤ or >5 times normal) ns –
Bilirubin (≤ or >34 μmol/ml) ns –
Severe biliary disease p=0.006 p<0.0001
PVT ns –
Main PVT without MAA targeting p=0.0014 p<0.0001
First line versus second or further lines ns –
Tumour involvement (< or ≥70 %) ns –
Hepatic reserve (< or ≥30 %) ns –
HILD (≥ 40 G, ≥60 Gy, ≥80 Gy, ≥100 Gy or ≥120 Gy) ns –
Hepatic reserve (< or ≥30 %) ns –
HILD (≥ 40 G, ≥60 Gy, ≥80 Gy) and hepatic reserve <30 % ns –
HILD ≥100 Gy and hepatic reserve <30 % p=0.032 ns




Fig. 7 ROC curves for the three toxicity scoring systems
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should also be evaluated for resin microspheres, as it
may be a valuable approach in a patient subpopulation
that still needs to be identified.
Liver tolerance was acceptable with permanent severe
liver function alterations observed in only six patients (i.e.
8.4 %), and was not increased in patients who underwent
treatment intensification. Several parameters have been
reported previously by different teams to be associated with
a high risk of liver toxicity, including ALT more than five
times normal [26], bilirubin level >34 μmol/ml [26], tumour
involvement >70 % [26], Child-Pugh class B [3, 5, 26] as
well as previous treatment [27]. In our study, these param-
eters were not significantly associated with severe liver
toxicity, which is probably because of our careful patient
selection, with only two patients with ALT levels more than
five times normal, two with bilirubin levels >2 mg, and two
with tumour involvement >70 %. In the univariate analysis,
severe underlying biliary disease (one patient with biliary
cirrhosis and another with diffuse biliary dilatation) was iden-
tified as being correlated with liver toxicity. In the multivariate
analysis, two other original and robust (i.e. significant) prog-
nostic factors for liver toxicity were identified, namely large
main PVTwithout MAA targeting and combination of HILD
>120Gy and hepatic reserve <30%. It should be noted that, in
our study, the HILD alone or the hepatic reserve alone was not
associated with a risk of liver toxicity. Using glass micro-
spheres, Chiesa et al. reported a higher risk of liver toxicity
(but taking into account grade 2 toxicity) with a mean lobe
dose exceeding 90 Gy for patients with Child-Pugh class >A5
(i.e. 80 % versus 50 % with a mean lobe dose <90 Gy) [13].
Using resin microspheres, liver toxicity of grade 3 or more
was reported in 21 % of patients with a liver median dose of
only 36 Gy [28].
The LTS identified in our study, integrating two major
MAA SPECT/CT parameters, was able to detect the risk of
severe liver toxicity with a sensitivity of 83 %, a negative
predictive value of 98 %, a positive predictive value of 71 %,
and an overall accuracy of 97 %. To our knowledge, a similar
liver toxicity scoring system has not previously been de-
scribed. Severe permanent liver toxicity was missed in only
one patient using the scoring system. As the patient showed
no recognized risk factors indicating liver toxicity, the liver
toxicity in this patient was possibly related to constitutional
radiation hypersensitivity. This LTS needs to be improved,
and its prognostic value confirmed prospectively in a larger,
and perhaps a less carefully selected patient population than
that in our study.
Finally, SIRT with glass microspheres is a fully person-
alized approach, which is the standard endpoint to aim for in
oncology [29, 30]. Using MAA SPECT/CT dosimetry, ad-
aptation of the injected activity in relation to the TD is
possible, and some patients may undergo treatment intensi-
fication in order to achieve a better response and improved
survival. On the other hand, the toxicity scoring system has
proven helpful in the identification of patients at high risk of
severe permanent liver toxicity, and can be used for exclud-
ing such patients from treatment. For example, when using
the B-SIRT concept in patients with PVT, MAA SPECT/CT
is able to identify, before therapy, a group of very poor
candidates (TD <205 Gy and/or no MAA targeting of
PVT) with an OS of only 3 months, and a group of good
candidates, representing 85 % of patients with PVT, with an
OS of 24.5 months. Such predictive factors and high OS
have not been reported previously for patients with PVT
regardless of the therapeutic approach used.
Concerning the technical aspects, the dosimetric model
used in this study is very simple, and is only able to provide
an evaluation of the mean dose of the hypervascularized le-
sions (in necrotic lesions, the software does not take into
account the volume of necrosis for definition of the VOI). A
mean dose evaluation may be insufficient for heterogeneous
lesions, and for the evaluation of HILD as well, as it does not
take into account heterogeneity of the irradiation and irradia-
tion via the tumour of the healthy peritumoral liver, an effect
that could prove significant for large tumours with enhanced
uptake. A voxel-based dosimetric model [5, 14, 31] may lead
to progress in this field.
Conclusion
This study involving a large patient cohort demonstrated the
predictive value of tumour dosimetry based on MAA
SPECT/CT using glass microspheres in terms of response
to SIRT, PFS, and OS. Tumour dosimetry data from MAA
SPECT/CT enables the clinical use of treatment intensifica-
tion or B-SIRT, with favourable clinical outcomes and low
rates of severe liver toxicity, especially in patients with
tumours larger than 5 cm and in patients with PVT. B-SIRT
is most likely a crucial concept for increasing the effective-
ness of SIRT in large lesions using glass microspheres. The
new LTS presented in this here allows accurate prediction of
severe permanent liver toxicity, thereby facilitating the se-
lection of appropriate candidates. Both the glass microsphere
B-SIRT concept and the LTS enable fully customized treat-
ment planning to be achieved, which is the aim in oncology.
In the near future, randomized studies are needed to confirm
these encouraging results and to better define the role of
glass microsphere B-SIRT in the therapeutic management
of HCC patients with or without PVT.
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